Amplia Therapeutics (ASX:ATX) Days Payable : 0.00 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics Days Payable?

Amplia Therapeutics's average Accounts Payable for the six months ended in Sep. 2023 was A$0.43 Mil. Amplia Therapeutics's Cost of Goods Sold for the six months ended in Sep. 2023 was A$0.00 Mil.

The historical rank and industry rank for Amplia Therapeutics's Days Payable or its related term are showing as below:

ASX:ATX's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.53
* Ranked among companies with meaningful Days Payable only.

Amplia Therapeutics's Days Payable stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00).

Amplia Therapeutics Days Payable Historical Data

The historical data trend for Amplia Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Days Payable Chart

Amplia Therapeutics Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Days Payable

Get a 7-Day Free Trial

Amplia Therapeutics Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Amplia Therapeutics's Days Payable

For the Biotechnology subindustry, Amplia Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Days Payable falls into.

Amplia Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Amplia Therapeutics's Days Payable for the fiscal year that ended in Mar. 2023 is calculated as

	Days Payable (A: Mar. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Mar. 2022 )	+	Accounts Payable (A: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (A: Mar. 2023 )	*	Days in Period
=	( (0.369	+	0.347)	/	2 )	/	0	*	365
=	0.358					/	0	*	365
=	N/A

Amplia Therapeutics's Days Payable for the quarter that ended in Sep. 2023 is calculated as:

	Days Payable (Q: Sep. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2023 )	+	Accounts Payable (Q: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
=	( (0.347	+	0.507)	/	2 )	/	0	*	365 / 2
=	0.427					/	0	*	365 / 2
=	N/A

Amplia Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (ASX:ATX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

INNMF:USA

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (ASX:ATX) Headlines

No Headlines